



Data Featured at EAN and ICNMD 2026

Johnson & Johnson

**European
Academy of
Neurology**

Geneva, Switzerland
27-30 June 2026

**International Congress on
Neuromuscular Diseases**

Florence, Italy
7-11 July 2026

Johnson & Johnson sponsored studies

Abstract number	Title	Presentation time (CEST)
PETUNIA study abstract		
A-26-17091	Pregnancy Enhanced Tracking with Neonatal and Infant Assessment (PETUNIA): Design of a Safety Study for Nipocalimab in Generalized Myasthenia Gravis	E-Poster Available on demand

VIVACITY data abstracts		
A-26-17148 EPO-0639	Efficacy of Nipocalimab in Patients Early in Their Disease Course of Generalized Myasthenia Gravis: Post Hoc Analysis of VIVACITY-MG3	E-poster Saturday, 27 June 12:55 - 13:00 Screen B6
A-26-17782 EPO-0653	Assessment of sustained health-related quality of life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalized Myasthenia Gravis	E-poster Saturday, 27 June 14:35 - 14:40 Screen B6
A-26-17088 EPO-0146	Quality of Life in Generalized Myasthenia Gravis Patients Achieving Sustained versus Transient Clinical Outcomes in the Phase 3 Vivacity-MG3 Trial	E-poster Saturday, 27 June 14:35 - 14:40 Screen B6
A-26-17754 EPO-0684	Effect of Nipocalimab on Pathogenic IgG and Complement Markers in Patients with Seropositive gMG: Exploratory Analysis in Vivacity-MG3 study	E-poster Sunday, 28 June 15:10 - 15:15 Screen B6
A-26-16923 EPO-0685	Efficacy of Nipocalimab in Patients with Lower Baseline Score of Myasthenia Gravis Activity of Daily Living in VIVACITY-MG3 study	E-poster Tuesday, 30 June 12:40 - 12:45 Screen B6
A-26-17210 EPO-0686	Corticosteroid Use in Nipocalimab-treated Japanese Patients with Generalized Myasthenia Gravis: Phase 3 Vivacity-MG3 Open-Label Extension Study	E-poster Tuesday, 30 June 12:45- 12:50 Screen B6
A-26-17151	Effect of Nipocalimab on Sustained Myasthenia Gravis Control During Infections: Post-hoc Analysis of the Vivacity-MG3 Study	E-poster Available on demand
A-26-17168	Efficacy of Nipocalimab in Adult Patients with None-to-Mild Ocular Manifestations of generalized Myasthenia Gravis in Phase 3 VIVACITY-MG3	E-poster Available on demand

RELIEF study abstracts		
A-26-17411 EPO-0656	Progression and Exacerbation Timing in Myasthenia Gravis: Real-World Evidence from France (RELIEF study)	E-poster Saturday, 27 June 14:50 - 14:55 Screen B6
A-26-17434 EPO-0657	One-Year Burden of Crises and Exacerbations in Myasthenia Gravis: Real-World Evidence from France (RELIEF Study)	E-poster Saturday, 27 June 14:55 - 15:00 Screen B6

ITC safety study abstract		
A-26-17149	Indirect comparison of Nipocalimab Safety Versus FcRn Blockers, C5 Complement Inhibitors, Rituximab and IVIg in Generalized Myasthenia Gravis	E-poster Available on demand

Johnson & Johnson sponsored studies		
Abstract number	Title	Presentation time (CEST)
VIVACITY data abstracts		
PP01.235	Efficacy of Nipocalimab in Patients with Myasthenia Gravis and Lower Baseline Activity of Daily Living	Wednesday, July 8, 10:30 – 11:15 CEST
PP01.236	Efficacy of Nipocalimab in Patients Early in Their Disease Course of Generalized Myasthenia Gravis	
PP01.189	Effect of Nipocalimab on Sustained Myasthenia Gravis Control During Infections: Posthoc Analysis of Vivacity-MG3 Study	
PP01.177	Assessing Relationship Between IgG-Levels and Infection Rate in Nipocalimab-Treated Patients with Generalized Myasthenia Gravis (Vivacity-MG3)	
PP01.208	Assessing Relationship Between Immunoglobulin-G Level and Nipocalimab Efficacy using Myasthenia Gravis-Activities of Daily Living Scale	
PP01.175	Long-term safety and efficacy of nipocalimab: Approximately 2 years follow-up results from Vivacity-MG3 open-label extension	

Johnson & Johnson sponsored studies

Abstract number	Title	Presentation time (CEST)
VIVACITY data abstracts		
PP01.209	Efficacy and Safety of Nipocalimab: Switch From 15-mg/kg Every-2-Week to 30-mg/kg Every-4-Week (VIVACITY-MG3 Open-Label Extension)*	Wednesday, July 8, 10:30 – 11:15 CEST
TBC	AChR-Autoantibody Detection and Therapeutic Assessment of Nipocalimab in Seronegative Patients with Myasthenia Gravis in Vivacity-MG3*	
PP01.210	Corticosteroid Usage in Patients with Generalized Myasthenia Gravis Receiving Nipocalimab: Phase 3 Vivacity-MG3 Open-Label Extension	

Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.